病院での死亡率の評価における病気の重度の重要性
J Green1, N Wintfeld, P Sharkey
1Department of Health Policy Research, New York University Medical Center/New York University School of Medicine 10016.
JAMA
|January 12, 1990
まとめ
ヘルス・ケア・ファイナンシング・アドミニストレーション (HCFA) のモデルでは,病院での死亡率を予測できていない. 患者の重症を考慮すると,予測の正確性が著しく向上し,有効な病院の品質評価のために必要な修正を提案します.
科学分野:
- 医療サービス 研究 医療サービス
- 医療情報工学 医療情報工学
- 公共衛生政策 公共衛生政策
背景:
- ヘルス・ケア・ファイナンシング・アドミニストレーション (HCFA) は,毎年,病院での死亡率の比較を公表しています.
- HCFAの予測モデルが患者の重症を考慮する上で適切であるかどうかについては懸念がある.
- 正確なリスク調整は,病院の有効な業績評価に不可欠です.
研究 の 目的:
- HCFAの病院死亡率モデルの予測能力を評価する.
- 死亡率の予測に患者の重症度を取り入れることによる影響を評価する.
- HCFAモデルが重症度に基づいて病院の質を適切に区別しているかどうかを判断する.
主な方法:
- HCFAの死亡率予測モデルを複製しました.
- 患者の重症度測定法 (入院時の主要な診断の段階) を含む2番目のモデルを開発しました.
- シミュレーションデータを用いて両モデルの予測性能 (R二乗) を比較した.
主要な成果:
- 元のHCFAモデルは,非常に限られた予測力 (平均R2は2.5%) を示した.
- HCFAモデルは,異なる患者重症度および病院における死亡率を区別できませんでした.
- 患者の重症をモデルに追加すると,予測力が8倍 (R2から21.5%) 増加し,死亡率の不一致が正常化しました.
結論:
- 現在のHCFAの死亡率予測モデルは,患者の入院の重症度に対して十分に敏感ではありません.
- 病院での死亡率を予測する上で,重大な改善は,重症度測定を含むことによって達成されます.
- HCFAの病院死亡率のリリースには,病院の品質と有効性を正確に反映するために,大幅な変更が必要です.
関連する概念動画
Healthcare Associated Infections II: Preventive Measures
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Causality in Epidemiology
Causality or causation is a fundamental concept in epidemiology, vital for understanding the relationships between various factors and health outcomes. Despite its importance, there's no single, universally accepted definition of causality within the discipline. Drawing from a systematic review, causality in epidemiology encompasses several definitions, including production, necessary and sufficient, sufficient-component, counterfactual, and probabilistic models. Each has its strengths and...
Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Assumptions of Survival Analysis
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
